A monoclonal antibody directed against lymphotoxin-α (LT-α) expressed by pathogenic T cells can prompt the clearance of these cells from the body (pages 766–773). The findings bring us one step closer to targeting only the cell populations that cause harm in autoimmune diseases while leaving beneficial arms of the immune system largely intact.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Caspi, R.R. Nat. Rev. Immunol. 8, 970–976 (2008).
Chiang, E. et al. Nat. Med. 15, 766–773 (2009).
O'Garra, A. & Arai, N. Trends Cell Biol. 10, 542–550 (2000).
Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V.K. Annu. Rev. Immunol. 27, 485–517 (2009).
Abbas, A.R. Genes Immun. 6, 319–331 (2005).
Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Cell 133, 775–787 (2008).
Shevach, E.M. Immunity 30, 636–645 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hansen, A., Caspi, R. Targeting lymphotoxin depletes pathogenic T cells. Nat Med 15, 732–733 (2009). https://doi.org/10.1038/nm0709-732
Issue Date:
DOI: https://doi.org/10.1038/nm0709-732
This article is cited by
-
The silent progression of metastatic malignancy during the treatment with soluble tumor necrosis factor receptor
Clinical Rheumatology (2010)